相关实验视频

Updated: May 11, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

在癌症免疫治疗中,TIM-3与PD-1合作:机制和前景

Zhuohong Yan¹, Chunmao Wang², Jinghong Wu¹

¹Department of Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.

Molecular biomedicine

|May 7, 2025

概括

结合T细胞免疫球蛋白和含有-3 (TIM-3) 抑制剂的粘素域与PD-1/PD-L1疗法的结合,有望克服癌症免疫逃避. 这种方法针对T细胞枯竭,提高了各种癌症的免疫疗法疗效.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

免疫检查点抑制剂 (ICI) 是关键的癌症疗法,但耐药性限制了疗效.
含有T细胞免疫球蛋白和含有-3 (TIM-3) 的粘素域和编程细胞死亡蛋白1 (PD-1) 在T细胞耗尽和免疫逃避中至关重要.
由于其在瘤微环境中的免疫抑制作用和表达,TIM-3是一个有前途的目标.

研究的目的:

系统地研究TIM-3和PD-1的生物学.
阐明TIM-3和PD-1/PD-L1在癌症免疫逃避中的机制.
分析正在进行的临床试验的组合TIM-3,PD-1和PD-L1抑制.

主要方法:

对基本的TIM-3和PD-1生物学进行了审查.
对TIM-3和PD-1/PD-L1介导的免疫逃避机制的分析.
对TIM-3和PD-1/PD-L1抑制剂的当前临床试验和抗体状况的全面审查.

主要成果:

TIM-3,PD-1和PD-L1轴在癌症免疫逃避中发挥着重要作用.
TIM-3 抑制剂与PD-1/PD-L1 抑制剂的联合治疗正在积极临床研究中.
目前正在进行的试验正在评估这些联合免疫疗法在各种癌症中的协同效应.

结论:

与PD-1/PD-L1抑制剂结合向TIM-3是一种有前途的策略,可以提高癌症免疫疗法的疗效.
进一步的研究和临床评估至关重要,以充分理解和利用TIM-3和PD-1/PD-L1联合封锁的潜力.

关键词:

临床试验中的临床试验.结合疗法是一种联合疗法.免疫检查点抑制剂免疫检查点抑制剂免疫治疗是一种免疫疗法.在PD-1/PD-L1中.在TIM-3中,TIM-3是TIM-3.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...